https://finance.yahoo.com/news/new-alzheimers-drug-from-biogen-eisai-gets-government-approval-but-faces-long-road-ahead-184008572.html
Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight.
Create an account or login to join the discussion